Qiu and Bae et al evaluated the expression of immune biomarkers in STS and found that increased CTLA4, PD-1, and LAG3 were connected to a good prognosis.[55,56] This result also indicated that STS patients who respond well to immunotherapy have higher pyroptosis scores, higher levels of immune cell infiltration, and stronger immune surveillance and immune-killing effects on tumor cells, which can explain the results of better OS in STS patients with high pyroptosis scores. The gene discussed is PDCD1; the disease is neoplasm.